BioSpace News Archive

Vertex Pharmaceuticals Incorporated announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director.

Shattuck Labs, Inc. announced that it will host an investor call on initial data from its ongoing frontline expansion cohorts in HR-MDS and TP53m AML and review data from the poster presentation featured at the 65th ASH Annual Meeting on Wednesday, December 13, 2023 at 8:00 a.m. ET.

Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.24 per share of its common stock, payable on January 26, 2024 to holders of record on December 29, 2023.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States.

ImmunoPrecise Antibodies Ltd., announced that it intends to offer and sell common shares in an underwritten public offering.

Kazia Therapeutics Limited announced the closing of its previously announced purchase and sale of up to an aggregate of 4,444,445 of the Company’s American Depositary Shares, each ADS representing ten ordinary shares of the Company, at a purchase price of $0.45 per ADS, in a registered direct offering.

Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.

Innovent Biologics, Inc. announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating sintilimab in combination with chemotherapy compared to chemotherapy for the first-line treatment of advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma was published in The Journal of the American Medical Association (JAMA, IF=120.7).

Bsense Bio Therapeutics Ltd. today announced the clinical candidate nomination of their drug candidate, BSEN760, a dual Kv7.2/3 and TRPV1 ion-channel modulator, which heralds a potential breakthrough in the treatment of chronic pain by potentially providing efficacy for a broad spectrum of chronic pain conditions devoid of side effects associated with current standard-of-care (SOC) treatments.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through Synthia™ retrosynthesis software application programing interface integration.